Compound-level reported effects BPC-157
Dosing 1 capsule 1-2 times daily on an empty stomach or as directed
I was welcomed by a friendly nurse who talked to me extensively about my treatment
lipolysis and visceral fat research CJC-1295 No DAC 10mg GHRH analogue
Cabozantinib Cabozantinib is an oral TKI targeting c-MET, vascular endothelial growth factor receptor (VEGFR)-1, VEGFR2 and VEGFR3, REarranged during Transfection (RET), tyrosine-protein kinase receptor UFO (AXL), KIT, tyrosine receptor kinase B (TRKB), fms like tyrosine kinase 3 (FLT-3), and TIE-2 [43], which showed preclinical and clinical activity in several types of tumors, including thyroid cancer [44, 45], renal cell carcinoma (RCC) [46], prostate [47], and NSCLC [48, 49]
Supports energy and mental focus